Close

SLC2A8

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This gene belongs to the solute carrier 2A family, which includes intracellular glucose transporters. Based on sequence comparison, the glucose transporters are grouped into three classes and this gene is a member of class II. The encoded protein, like other members of the family, contains several conserved residues and motifs and 12 transmembrane domains with both amino and carboxyl ends being on the cytosolic side of the membrane. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Nov 2012]
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-LY719 Anti-SLC2A8 (XR549) h(41BB-CD3ζ) CAR, pCDCAR1 Human XR549 Human scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2359 Anti-SLC2A8(XR549) h(CD28-CD3ζ) CAR, pCDCAR1 Human XR549 Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1022-ZP577 Anti-SLC2A8 (VB1-050) h(41BB-CD3ζ) CAR, pCDCAR1 Human VB1-050 Human scFv-41BB-CD99ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1022-ZP578 Anti-SLC2A8 (VB1-050) h(CD28-CD3ζ) CAR, pCDCAR1 Human VB1-050 Human scFv-CD28-CD99ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.